One such study is the randomized prospective phase II trial (NCT02621021), which is being carried out to find out if patients with metastatic melanoma may experience higher response rates when pembrolizumab is added to TIL/IL-2 therapy (160). Here, IL2 is linked to metastatic melanoma.